CONMED CORPORATION
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.5M | $955.1M |
| Cost of Revenue | — | $624.2M | $574.0M | $568.5M | $474.2M | $442.6M | $402.2M | $430.4M |
| Gross Profit | — | $750.5M | $733.0M | $676.2M | $571.2M | $568.0M | $460.3M | $524.7M |
| Gross Margin | — | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% |
| Operating Expenses | ||||||||
| Research & Development | — | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M | $40.5M | $45.5M |
| SG&A Expense | — | $592.0M | $478.3M | $503.0M | $454.0M | $414.8M | $373.8M | $400.1M |
| Operating Income | — | $102.6M | $200.3M | $120.6M | $70.1M | $109.7M | $46.0M | $79.1M |
| Operating Margin | — | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% |
| Interest Expense | — | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M | $44.1M | $42.7M |
| Pretax Income | — | $71.1M | $163.0M | $80.8M | $-70.9M | $73.1M | $1.6M | $31.2M |
| Income Tax Expense | — | $24.1M | $30.6M | $16.4M | $9.7M | $10.6M | $-7.9M | $2.6M |
| Net Income | — | $47.1M | $132.4M | $64.5M | $-80.6M | $62.5M | $9.5M | $28.6M |
| Net Margin | — | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% |
| EPS (Basic) | — | $1.52 | $4.29 | $2.10 | $-2.68 | $2.14 | $0.33 | $1.01 |
| EPS (Diluted) | — | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 | $0.32 | $0.97 |
| Shares Outstanding (Basic) | 30.8M | 31.0M | 30.8M | 30.7M | 30.0M | 29.2M | 28.6M | 28.3M |
| Shares Outstanding (Diluted) | 30.8M | 31.1M | 31.2M | 31.5M | 30.0M | 32.2M | 29.5M | 29.5M |
| Dividends Per Share | — | $0.60 | $0.80 | $0.80 | $0.80 | $0.80 | $0.80 | $0.80 |